A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 336,300 shares of KYMR stock, worth $14.8 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
336,300
Previous 367,000 8.37%
Holding current value
$14.8 Million
Previous $11 Million 45.31%
% of portfolio
0.04%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$30.16 - $52.4 $925,912 - $1.61 Million
-30,700 Reduced 8.37%
336,300 $15.9 Million
Q2 2024

Aug 14, 2024

BUY
$29.85 - $39.42 $4.71 Million - $6.22 Million
157,900 Added 75.51%
367,000 $11 Million
Q1 2024

May 15, 2024

BUY
$22.9 - $43.57 $874,780 - $1.66 Million
38,200 Added 22.35%
209,100 $8.41 Million
Q4 2023

Feb 14, 2024

SELL
$10.97 - $26.84 $193,072 - $472,384
-17,600 Reduced 9.34%
170,900 $4.35 Million
Q3 2023

Nov 14, 2023

BUY
$13.9 - $23.88 $360,010 - $618,492
25,900 Added 15.93%
188,500 $2.62 Million
Q2 2023

Aug 14, 2023

SELL
$22.4 - $34.92 $884,800 - $1.38 Million
-39,500 Reduced 19.54%
162,600 $3.74 Million
Q1 2023

May 15, 2023

BUY
$24.84 - $38.75 $466,992 - $728,500
18,800 Added 10.26%
202,100 $5.99 Million
Q4 2022

Feb 14, 2023

BUY
$19.57 - $30.92 $103,721 - $163,876
5,300 Added 2.98%
183,300 $4.58 Million
Q3 2022

Nov 14, 2022

SELL
$20.91 - $34.27 $1.12 Million - $1.84 Million
-53,700 Reduced 23.18%
178,000 $3.88 Million
Q2 2022

Aug 15, 2022

BUY
$14.13 - $42.55 $2.9 Million - $8.72 Million
204,900 Added 764.55%
231,700 $4.56 Million
Q1 2022

May 16, 2022

BUY
$35.3 - $64.68 $755,419 - $1.38 Million
21,400 Added 396.3%
26,800 $1.13 Million
Q4 2021

Feb 14, 2022

BUY
$49.91 - $65.56 $269,514 - $354,024
5,400 New
5,400 $343,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.41B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.